These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7554045)

  • 1. Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.
    Reichelová V; Juliusson G; Spasokoukotskaja T; Eriksson S; Liliemark J
    Cancer Chemother Pharmacol; 1995; 36(6):524-9. PubMed ID: 7554045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
    Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
    Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL).
    Albertioni F; Lindemalm S; Eriksson S; Juliusson G; Liliemark J
    Adv Exp Med Biol; 1998; 431():693-7. PubMed ID: 9598154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
    Månsson E; Spasokoukotskaja T; Sällström J; Eriksson S; Albertioni F
    Cancer Res; 1999 Dec; 59(23):5956-63. PubMed ID: 10606241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB.
    Cardoen S; Van Den Neste E; Smal C; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F
    Clin Cancer Res; 2001 Nov; 7(11):3559-66. PubMed ID: 11705877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
    Graham MA; Senan S; Robin H; Eckhardt N; Lendrem D; Hincks J; Greenslade D; Rampling R; Kaye SB; von Roemeling R; Workman P
    Cancer Chemother Pharmacol; 1997; 40(1):1-10. PubMed ID: 9137522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
    Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
    J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.
    Han T; Fernandez M; Chou TC; Agarwal RP
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):609-16. PubMed ID: 16044347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
    Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
    Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.
    Saven A; Kawasaki H; Carrera CJ; Waltz T; Copeland B; Zyroff J; Kosty M; Carson DA; Beutler E; Piro LD
    J Clin Oncol; 1993 Apr; 11(4):671-8. PubMed ID: 8097527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of anticancer nucleoside analogs by human mitochondrial deoxyguanosine kinase.
    Zhu C; Johansson M; Permert J; Karlsson A
    Biochem Pharmacol; 1998 Oct; 56(8):1035-40. PubMed ID: 9776315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
    Hapke DM; Stegmann AP; Mitchell BS
    Cancer Res; 1996 May; 56(10):2343-7. PubMed ID: 8625309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in kinetic properties of pure recombinant human and mouse deoxycytidine kinase.
    Johansson M; Karlsson A
    Biochem Pharmacol; 1995 Jul; 50(2):163-8. PubMed ID: 7632159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment.
    Arnér ES
    Leuk Lymphoma; 1996 Apr; 21(3-4):225-31. PubMed ID: 8726403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia.
    Albertioni F; Lindemalm S; Reichelova V; Pettersson B; Eriksson S; Juliusson G; Liliemark J
    Clin Cancer Res; 1998 Mar; 4(3):653-8. PubMed ID: 9533533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
    Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB
    J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity.
    Spasokoukotskaja T; Sasvári-Székely M; Keszler G; Albertioni F; Eriksson S; Staub M
    Eur J Cancer; 1999 Dec; 35(13):1862-7. PubMed ID: 10674004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver.
    Albertioni F; Hassan M; Silberring J; Liliemark J
    Eur J Drug Metab Pharmacokinet; 1995; 20(3):225-32. PubMed ID: 8751045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells.
    Smal C; Cardoen S; Bertrand L; Delacauw A; Ferrant A; Van den Berghe G; Van Den Neste E; Bontemps F
    Biochem Pharmacol; 2004 Jul; 68(1):95-103. PubMed ID: 15183121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion.
    Sonderegger T; Betticher DC; Cerny T; Lauterburg BH
    Cancer Chemother Pharmacol; 2000; 46(1):40-2. PubMed ID: 10912576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.